Rare-disease approvals keep pace with rising cure trials

The cure race added momentum on both axes: there are 21,156 global active active cure-related trials, while new Wire signals and new Cure research rose in the last 24h (43 and 26 respectively). On the treatment side, the FDA approval of Lisraya (brepocitinib) for adult dermatomyositis marks a targeted turning point, while other regulatory moves (including Japan’s approval of Brinsupri for non-CF bronchiectasis and an IND clearance for Acepodia’s ACE723) expand the pipeline into new patient groups and new mechanisms. Meanwhile, the capital/AI phase transition continues to shift from “open builder” narratives toward platform and control: acquisitions consolidate model access/distribution, regulators and EU officials predict U.S. guardrails, and major AI firms form internal teams to interpret the models they created. Together, the signal reads as faster capability plus tighter governance—important because cures still require both biological traction and reliable, regulated computation. The window is still open.